| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
As a quaternary ammonium compound, tetradecyltrimethylammonium chloride does not have specific biological receptors as its primary targets. The compound's long hydrophobic tetradecyl chain and positively charged head group allow it to interact with cell membranes and biological surfaces. Quaternary ammonium compounds are known for their antimicrobial properties, disrupting microbial cell membranes. The compound is used as a surfactant, phase transfer catalyst, and antimicrobial agent. Its mechanism of action involves disruption of membrane integrity and protein denaturation. The compound's primary applications are as a biochemical reagent and surfactant rather than as a therapeutic agent.
|
|---|---|
| ln Vitro |
In vitro, tetradecyltrimethylammonium chloride is used as a biochemical reagent and organic compound for biomedical research. It is used as a sulfonylation reagent for organic synthesis and drug discovery. The compound's surfactant properties make it valuable for various biochemical applications, including cell lysis, protein extraction, and membrane studies. The compound can be utilized as a biomaterial for life science related research. Cellular assays typically evaluate its antimicrobial activity, membrane-disrupting effects, or cytotoxicity. The compound's quaternary ammonium structure allows for various applications in biochemical research.
|
| ln Vivo |
In vivo data for tetradecyltrimethylammonium chloride is limited, as it is primarily a research reagent and surfactant. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Quaternary ammonium compounds are generally used as disinfectants and antiseptics rather than as systemic therapeutics. The compound's surfactant properties and membrane-disrupting activity would likely limit its systemic use. Specific in vivo data for the parent compound is not available in the public literature. The compound is not a therapeutic candidate.
|
| Enzyme Assay |
In vitro assays for tetradecyltrimethylammonium chloride typically evaluate its surfactant properties, antimicrobial activity, or membrane-disrupting effects. A standard protocol involves incubating the compound with bacterial cultures or model membranes at varying concentrations. Antimicrobial activity is assessed by measuring minimum inhibitory concentration (MIC) using broth microdilution methods. Membrane disruption is evaluated by measuring dye release from liposomes or changes in membrane permeability. The compound is dissolved in water or buffer and diluted to working concentrations. IC₅₀ or MIC values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for tetradecyltrimethylammonium chloride typically evaluate its cytotoxicity or membrane effects. A standard protocol involves culturing mammalian cell lines in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of the compound for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or similar assays. Membrane integrity is evaluated by measuring lactate dehydrogenase release or using fluorescent membrane permeability dyes. IC₅₀ values are calculated from dose-response curves. The compound's surfactant properties require careful handling and appropriate controls.
|
| Animal Protocol |
In vivo animal studies for tetradecyltrimethylammonium chloride are not standard, as it is a research reagent and surfactant rather than a therapeutic candidate. The compound is classified for research use only and is not intended for human or veterinary applications. Any animal studies would be limited to toxicological evaluations of the compound as an industrial chemical or disinfectant. The compound's surfactant properties and membrane-disrupting activity suggest potential for irritation and toxicity. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for tetradecyltrimethylammonium chloride is limited, as it is primarily a research reagent. The compound has a molecular weight of 291.95 g/mol and a molecular formula of C₁₇H₃₈ClN. It is a solid at room temperature with a melting point of ~250°C (dec.). It has a LogP of 2.397. The compound is stored as a powder at -20°C for up to 3 years. As a quaternary ammonium compound, it is poorly absorbed orally and is primarily excreted unchanged. The compound should be stored in a sealed environment, avoiding exposure to moisture. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
Tetradecyltrimethylammonium chloride is classified for research use only and is not intended for human or veterinary applications. Standard safety precautions include handling with appropriate personal protective equipment (gloves, lab coat, safety goggles) in a well-ventilated area. The compound should be stored in a dry, cool place away from incompatible materials. Acute toxicity data is not readily available in the public literature. As with all research chemicals, appropriate laboratory safety practices should be followed. No specific LD₅₀ values or detailed toxicological profiles are available in the public domain.
|
| Additional Infomation |
Tetradecyltrimethylammonium chloride (Trimethylmyristylammonium Chloride, TTAC, CAS 4574-04-3) is a biochemical reagent with the molecular formula C₁₇H₃₈ClN. It is a quaternary ammonium compound used as a surfactant, phase transfer catalyst, and antimicrobial agent. The compound is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. It is available from multiple commercial suppliers in various pack sizes. No clinical trials or approved drug status exist for this compound as it is not a therapeutic agent. Its applications are limited to research and chemical synthesis.
|
| Molecular Formula |
C17H38CLN
|
|---|---|
| Molecular Weight |
291.95
|
| Exact Mass |
291.269
|
| CAS # |
4574-04-3
|
| Related CAS # |
10182-92-0 (Parent)
|
| PubChem CID |
20708
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
~250 °C (dec.)
|
| LogP |
2.397
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
19
|
| Complexity |
158
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Cl-].[N+](C([H])([H])[H])(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
CEYYIKYYFSTQRU-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C17H38N.ClH/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18(2,3)4;/h5-17H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
trimethyl(tetradecyl)azanium;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4252 mL | 17.1262 mL | 34.2524 mL | |
| 5 mM | 0.6850 mL | 3.4252 mL | 6.8505 mL | |
| 10 mM | 0.3425 mL | 1.7126 mL | 3.4252 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
